This article is more than 5 years old. Information may no longer be current.

Lupin launches InspiraChamber asthma device in US

Lupin Pharmaceuticals has launched the InspiraChamber Anti-Static Valved Holding Chamber under a licensing agreement with InspiRX, according to a press release.

The agreement allows Lupin exclusive rights to promote, distribute and market the device in the United States.

The device, developed by InspiRX, was designed to improve delivery of aerosol therapies for patients with asthma. It was approved by the FDA in 2013.

“The launch demonstrates Lupin’s commitment to grow its brand franchise in the U.S. and bring meaningful products to patients in the country,” Vinita Gupta, CEO of Lupin Ltd., said in the release. “The launch also heralds Lupin’s entry into the larger U.S. inhalation and related markets.”